| Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial C Gridelli, F Perrone, C Gallo, S Cigolari, A Rossi, F Piantedosi, ... Journal of the National Cancer Institute 95 (5), 362-372, 2003 | 1067 | 2003 |
| Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer Elderly Lung Cancer Vinorelbine Italian Study Group Journal of the National Cancer Institute 91 (1), 66-72, 1999 | 769 | 1999 |
| Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy … P Maione, F Perrone, C Gallo, L Manzione, FV Piantedosi, S Barbera, ... Journal of Clinical Oncology 23, 6865-6872, 2005 | 563 | 2005 |
| Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials M Di Maio, C Gallo, NB Leighl, MC Piccirillo, G Daniele, F Nuzzo, ... Journal of Clinical oncology 33 (8), 910-915, 2015 | 450 | 2015 |
| Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma GL Ceresoli, PA Zucali, AG Favaretto, F Grossi, P Bidoli, G Del Conte, ... J Clin Oncol 24 (9), 1443-1448, 2006 | 365 | 2006 |
| Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with … GV Scagliotti, J Von Pawel, S Novello, R Ramlau, A Favaretto, F Barlesi, ... Journal of Clinical Oncology 33 (24), 2667-2674, 2015 | 276 | 2015 |
| First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts, V Gebbia, P Maione, ... Journal of Clinical Oncology 30 (24), 3002-3011, 2012 | 276 | 2012 |
| A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors I Petrini, PS Meltzer, IK Kim, M Lucchi, KS Park, G Fontanini, J Gao, ... Nature genetics 46 (8), 844-849, 2014 | 247 | 2014 |
| Long-term survival and prognostic factors in thymic epithelial tumours F Rea, G Marulli, R Girardi, L Bortolotti, A Favaretto, A Galligioni, F Sartori European journal of cardio-thoracic surgery 26 (2), 412-418, 2004 | 217 | 2004 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 214 | 2017 |
| Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results F Rea, G Marulli, L Bortolotti, C Breda, AG Favaretto, L Loreggian, ... Lung cancer 57 (1), 89-95, 2007 | 176 | 2007 |
| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 172 | 2023 |
| Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non–small cell lung cancer MA Molina-Vila, J Bertran-Alamillo, A Gascó, C Mayo-de-las-Casas, ... Clinical Cancer Research 20 (17), 4647-4659, 2014 | 146 | 2014 |
| Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric Phase II study AG Favaretto, SML Aversa, A Paccagnella, VDP Manzini, V Palmisano, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 144 | 2003 |
| Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised, phase 3 trial PM Ellis, FA Shepherd, M Millward, F Perrone, L Seymour, G Liu, S Sun, ... The Lancet Oncology 15 (12), 1379-1388, 2014 | 138 | 2014 |
| Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy PA Zucali, T De Pas, G Palmieri, A Favaretto, A Chella, M Tiseo, M Caruso, ... Journal of Clinical Oncology 36 (4), 342-349, 2018 | 132 | 2018 |
| Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials GL Ceresoli, B Castagneto, PA Zucali, A Favaretto, M Mencoboni, ... British journal of cancer 99 (1), 51-56, 2008 | 132 | 2008 |
| Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies C Gridelli, P Maione, A Illiano, FV Piantedosi, A Favaretto, A Bearz, ... J Clin Oncol 25 (29), 4663-4669, 2007 | 128 | 2007 |
| Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study C Gridelli, C Gallo, A Ceribelli, V Gebbia, T Gamucci, F Ciardiello, ... The lancet oncology 8 (6), 500-512, 2007 | 112 | 2007 |
| Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma GL Ceresoli, PA Zucali, M Mencoboni, M Botta, F Grossi, D Cortinovis, ... British journal of cancer 109 (3), 552-558, 2013 | 110 | 2013 |
giovanni ceresoliASST Valle Olona, Oncology DepartmentVerified email at asst-valleolona.it
